Treatment of meningococcal purpura fulminans;Traitement du purpura fulminans méningococcique

Archives de Pediatrie

Volumn 8, Issue SUPPL. 4, 2001, Pages 677-688

  Leclerc, F ^a   Noizet, O ^a   Dorkenoo, A ^a   Cremer, R ^a   Leteurtre, S ^a   Sadik, A ^a   Fourier, C ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Child; Meningococcal infections; Purpura; Treatment

Indexed keywords

AMRINONE; ANTIBIOTIC AGENT; ANTITHROMBIN; BICARBONATE; CALCIUM CHLORIDE; CATECHOLAMINE; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; DOBUTAMINE; DOPAMINE; GLUCOSE; GLYCERYL TRINITRATE; HIRUDIN; HYDROCORTISONE; MAGNESIUM SULFATE; MENINGOCOCCUS VACCINE; MILRINONE; NITROPRUSSIDE SODIUM; NORADRENALIN; PHOSPHATE; POTASSIUM; PROTEIN C; SODIUM; STEROID; TETRACOSACTIDE; TISSUE PLASMINOGEN ACTIVATOR; UNINDEXED DRUG; VASODILATOR AGENT; VASOPRESSIN;

AMPUTATION; ANTIBIOTIC THERAPY; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE SEVERITY; EARLY DIAGNOSIS; ECCHYMOSIS; FLUID THERAPY; FULMINATING PURPURA; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE; LUMBAR PUNCTURE; MENINGOCOCCOSIS; MORTALITY; PATIENT REFERRAL; PUBLIC HEALTH; SEPTIC SHOCK; SKIN GRAFT; SKIN NECROSIS; STEROID THERAPY; SURVIVAL;

EID: 10844253907     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(01)80182-2     Document Type: Conference Paper

References (61)

1. Acute infectious purpura fulminans: Pathogenesis and medical management
2. Update on meningococcal disease with emphasis on pathogenesis and clinical management
3. Pathophysiology of meningococcal sepsis in children
4. A myocardial cytotoxic process in involved in the cardiac dysfunction of meningococcal septic shock
5. Microcirculatory oxygenation and shunting in sepsis and shock
6. Protein C and S deficiency in severe infectious purpura of children: A collaborative study of 40 cases
7. Disseminated intravascular coagulation and purpura fulminans secondary to infection
8. Les infections à méningocoque en France en 1998 et 1999
9. The early management of meningococcal disease
10. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal spetic shook
11. Do new strategies in meningococcemia produce better outcomes?
12. Are there specific haemostatic abnormalities in children surviving septic shock with purpura and having skin necrosis or limb ischaemia that need skin grafts or limb amputations?
13. Incidence of bacteremia in infants and children with fever and petechiae
14. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock
15. Sepsis in neonates and children: Definitions, epidemiology, and outcome
16. Avoidable deficiencies in the delivery of health care to children with meningococcal disease
17. Early management of meningococcal disease
18. Emergency management of meningococcal disease
19. Avis du Conseil superieur d'Hygiene publique de France du 10 mars 2000 sur la conduite immediate a tenir en cas de suspicion clinique de purpura fulminans et sur la definition des cas de meningite a meningocoque et de meningococcemie dans l'Entourage desquels une prophylaxie doit etre envisagee et qui doivent etre notifies a l'Autorite sanitaire
20. Meningococcal disease in a large urban population (Barcelona, 1987-1992): Predictors of dismal prognosis
21. Outcome of pre-hospital antibiotic treatment of meningococcal disease
22. Antibiotic treatment of children with unsuspected meningococcal disease
23. Scores de gravité à l'admission des méningococcémies
24. Can generic scores (PRISM, PIM) replace specific scores in predicting the outcome of presumed meningococcal septic shock in children?
25. Purpura fulminans: Nécessité d'un diagnostic et d'une prise en charge précoces
26. Recognition, treatment and complications of meningococcal disease
27. Corticothérapie au cours du choc septique et du syndrome de détresse respiratoire aiguë
28. Admission cortisol and adrenocorticotrophic hormone levels in children with meningococcal disease: Evidence of adrenal insufficiency?
29. Endocrine and metabolic responses in children with meningoccocal sepsis: Striking differences between survivors and non survivors
30. Adrenal insufficiency in septic shock
31. Intravenous immunoglobulin for treating sepsis and septic shock
32. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis
33. Recommandations pour la pratique clinique. Remplissage vasculaire au cours des hypovolémies relatives ou absolues
34. Utilisation des catécholamines au cours du choc septique (adultes-enfants)
35. Hemodynamic support in fluid-refractory pediatric septic shock
36. Hemodynamic support in septic shock
37. Quantitated left ventricular systolic mechanics in children with septic shock utilizing noninvasive wall-stress analysis
38. Effects of perfusion pressure on tissue perfusion in septic shock
39. Early hyperlactataemia in critically ill children
40. 21) as adjunctive treatment for children with severe meningococcal sepsis: A randomised trial
41. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock
42. Early filtration and mortality in meningococcal septic shock?
43. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia
44. Administration of protein C concentrate in children with severe meningococcal disease results in dose-related increases in serum protein C and activated protein C levels
45. Efficacy and safety of recombinant human activated protein C for severe
46. Use of tissue plasminogen activator in children with fulminant meningococcaemia
47. Tissue factor pathway inhibitor (TFPI) levels in the plasma and urine of children with meningococcal disease
48. Prophylaxie des infections à méningocoque
49. Clinical and hematologic features do not reliably identify children with unsuspected meningococcal disease
50. Recognising meningococcal disease in primary care: Qualitative study of how general practitioners process clinical and contextual information
51. Who spots the spots? Diagnosis and treatment of early meningococcal disease in children
52. Fcγreceptor IIa (CD32) polylorphism in fulminant meningococcal septic shock in children
53. Association of human FcγRIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease
54. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease
55. Variation in the tumor necrosis factor-αgene promoter region may be associated with death from meningococcal disease
56. An interkeukin-1 genotype is associated with fatal outcome of meningococcal disease
57. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock
58. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease
59. The insertion/deletion polymorphism in the t-PA gene does not significantly affect outcome of meningococcal disease
60. Effect of the factor V Leiden mutation on the severity of meningococcal disease
61. Infections à méningocoques. Développement des vaccins conjugués